Strong REZOLVE-AA Study Results Drive Analyst Confidence in Nektar Therapeutics (NKTR) [Yahoo! Finance]
Nektar Therapeutics: Rezpeg's Phase 2b Alopecia Areata Results Leave Many Questions [Seeking Alpha]
Why Analysts Think Nektar Therapeutics Could Be Undervalued After Rezpeg Trial Momentum Grows [Yahoo! Finance]
Nektar Therapeutics (NASDAQ:NKTR) had its price target raised by analysts at BTIG Research from $100.00 to $118.00. They now have a "buy" rating on the stock.
Nektar Therapeutics (NASDAQ:NKTR) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..